Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any eye disorder in which the cause of the disease is a mutation in the PAX6 gene.
No HPO annotations are available for this condition.
PAX6-related aniridia occurs either as an isolated ocular abnormality or as part of the Wilms tumor-aniridia-genital anomalies-retardation (WAGR) syndrome. Aniridia, a congenital eye anomaly, is usually detected at birth if fully penetrant. It is often the presenting feature of WAGR syndrome; children with WAGR syndrome are at significant risk of developing Wilms tumor during early childhood.
PAX6-related aniridia includes isolated aniridia without systemic involvement and the Wilms tumor-aniridia-genital anomalies-retardation (WAGR) syndrome. No formal diagnostic criteria have been published.
PAX6-related isolated aniridia should be suspected in probands who have the following clinical and imaging findings of aniridia with no other associated systemic abnormalities.
Clinical findings
Source: GeneReviews — "PAX6-Related Aniridia"
No approved treatments are currently available for PAX6-related ocular dysgenesis. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with aniridia (whether isolated or part of Wilms tumor-aniridia-genital anomalies-retardation [WAGR] syndrome), the following are recommended:
Evaluation of visual acuity (not easily performed in infants) and documentation of the degree of iris tissue deficiency, and the presence of foveal and optic nerve hypoplasia in order to predict future visual function.
Amblyopia and refractive error. Children younger than age eight years should be monitored every four to six months for refractive errors and detection and treatment of incipient or actual amblyopia (strabismic, refractive, or sensory). Glasses and other visual aids should be provided to optimize access to educational materials. Detection of later-onset eye pathology. Individuals with aniridia should have an annual ophthalmology review to detect issues such as corneal changes, raised intraocular pressure, and cataracts. Glaucoma. Individuals with aniridia should undergo annual glaucoma screening throughout life including:
No clinical trials have been registered for PAX6-related ocular dysgenesis.
7 publications have been identified in PubMed for PAX6-related ocular dysgenesis. Research spans Review / Meta-Analysis (43%), Diagnostic / Biomarker (29%), and Case Report / Case Series (14%).
Saha BC (2026). [PMID: 41936534](https://pubmed.ncbi.nlm.nih.gov/41936534/). *Eur J Ophthalmol*. [Review / Meta-Analysis]
Arcot Sadagopan K (2025). [PMID: 40083070](https://pubmed.ncbi.nlm.nih.gov/40083070/). *Ophthalmic Genet*. [Case Report / Case Series]
Hall J (2025). [PMID: 40138169](https://pubmed.ncbi.nlm.nih.gov/40138169/). *Ophthalmol Ther*. [Review / Meta-Analysis]
Zobor D (2025). [PMID: 41235862](https://pubmed.ncbi.nlm.nih.gov/41235862/). *Invest Ophthalmol Vis Sci*. [Diagnostic / Biomarker]
Bastelica P (2025). [PMID: 39368260](https://pubmed.ncbi.nlm.nih.gov/39368260/). *J Fr Ophtalmol*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 3:00 PM UTC
Common questions about PAX6-related ocular dysgenesis
Aniridia is a pan ocular disorder affecting the cornea, iris, intraocular pressure, lens, fovea, and optic nerve. The phenotype is variable between and within families; however, affected individuals usually show little variability between the two eyes. Individuals with aniridia characteristically show nystagmus, impaired visual acuity (usually 20/100 - 20/200), and foveal hypoplasia.
Source: GeneReviews — "PAX6-Related Aniridia"
Heterozygous pathogenic variants in the following genes are included in the differential diagnosis of PAX6-related aniridia:
FOXC1. Phenocopies exist and include dominant alleles of FOXC1, which can cause diagnostic difficulties .
PITX2.
PITX3.
Unknown.
could not identify the cause of aniridia in 20 individuals despite PAX6, FOXC1, and PITX2 sequence analysis, FISH, and aCGH, suggesting that there may be further genetic heterogeneity with potentially new disease loci and/or novel mutational mechanisms.
Source: GeneReviews — "PAX6-Related Aniridia"
Biomarker and diagnostic research for PAX6-related ocular dysgenesis has been reported in the published literature.
Evaluation for the degree of involvement of the cornea and lens and measurement of intraocular pressure, as they are potentially treatable causes of further visual reduction; however, treatable changes may not appear until later in life.
Consultation with a clinical geneticist and/or genetic counselor
To establish the extent of disease and needs in an individual diagnosed with WAGR syndrome, the following are recommended:
Evaluation by a pediatrician to assess growth and feeding
Evaluation for Wilms tumor
Evaluation by a urologist for urogenital abnormalities
Developmental assessment
Aniridia. Simple measures are often the most important:
Source: GeneReviews — "PAX6-Related Aniridia"
It has been suggested that intraocular surgery may increase the likelihood of (or exacerbate existing) keratopathy , and repeated intraocular surgery does predispose to the rare but severe aniridic fibrosis syndrome. Affected individuals should therefore be counseled about these risks before undertaking such surgery.
Source: GeneReviews — "PAX6-Related Aniridia"
Ongoing research is investigating the role and success of limbal stem cell transplantation and ocular mucous membrane cell transplantation for keratopathies associated with limbal stem cell failure, including aniridia . A Phase II randomized, double-masked, placebo-controlled study of ataluren in individuals with aniridia caused by pathogenic nonsense variants in PAX6 is under way (ClinicalTrials.gov Identifier: NCT02647359). This is based on preclinical evidence that the small-molecule drug ataluren can effectively suppress the nonsense mutation in the Pax6 mouse model, generating full-length functional protein that reversed the developmental defect following postnatal drug administration . Search ClinicalTrials.
Source: GeneReviews — "PAX6-Related Aniridia"
View trials for PAX6-related ocular dysgenesis
Measurement of intraocular pressure;
Optic disc examination;
Visual field assessment when possible.
Note: Assessment of the optic disc and visual field may be difficult in the presence of media opacities and nystagmus. Optic disc photography is a useful method of monitoring optic disc changes. Aniridic fibrosis syndrome. Individuals with aniridia with a history of multiple ocular procedures (penetrating keratoplasty, IOLs, and drainage tube insertion) should be monitored for aniridic fibrosis syndrome .
Wilms tumor. Children with aniridia and a WT1 deletion require kidney ultrasound examinations every three months and follow up by a pediatric oncologist until they reach age eight years. See Wilms Tumor Predisposition. (Those without deletion of the WT1 locus are at very low risk for Wilms tumor and do not require such screening .
Source: GeneReviews — "PAX6-Related Aniridia"
Dentel A (2024). [PMID: 38227763](https://pubmed.ncbi.nlm.nih.gov/38227763/). *J Neuroophthalmol*. [Diagnostic / Biomarker]